Mead Johnson has welcomed a crucial court victory in the US state of Missouri, where a jury cleared the company of allegations that its preterm nutrition products caused necrotising enterocolitis (NEC) in vulnerable babies. The condition, which affects premature infants and can be life-threatening, had been at the centre of high-profile legal action – but experts now say that evidence presented during the trial shows it's not as simple as blaming a single product.
According to Mead Johnson, the trial testimony highlighted the complex causes of NEC, with no conclusive link established between its preterm nutrition products and the condition. The company says this verdict is a significant win for parents who have entrusted their babies' care to these specialist products, which provide essential nutrition when mother's or donor milk isn't available.
Mead Johnson has always maintained that its preterm hospital nutrition products are safe and effective, and are recommended by neonatologists as part of the standard of care in neonatal intensive care units (NICUs) for premature babies. The company is committed to continuing this high level of care, as demonstrated by its over 120 years of experience developing nutritional solutions tailored to the complex needs of all infants.
The verdict in the Collins case marks a significant milestone in Mead Johnson's ongoing defence against similar product liability lawsuits. While there are still concerns about the safety and efficacy of preterm nutrition products, this decision is seen as a positive step forward for parents who rely on these specialist products to care for their vulnerable babies.